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Background: The host’s immune system is crucially involved in cancer development and progression. The ratio of
regulatory to effector T-cells, as well as the interplay of T-cells with therapeutic agents, impact on cancer prognosis.
The current study aimed to comparatively investigate the effect of metronomic and standard chemotherapy on the
number and functionality of peripheral regulatory and effector T-cells in cancer patients.
Methods: CD4+CD25+ regulatory and CD4+CD25- effector T-cells were purified from the peripheral blood of 36
cancer patients and co-cultured in the presence of a polyclonal stimulus. The proliferative capacity and frequency
of CD4+CD25+/CD4+CD25- T-cells were analysed before and during various chemotherapeutic regimes, by ELISA
and flow cytometry, respectively.
Results: Chemotherapy shifted immune responses in favour of regulatory T-cells. The relative ratio of regulatory to
effector T-cells increased, and the T-cell-mediated suppressive activity of regulatory on effector T-cells was
augmented. This effect was more profound in metronomic than in standard chemotherapeutic approaches.
Moreover, an association between the chemotherapy strategy followed and the mode of action of specific drugs
(anti-mitotic, anti-DNA) was revealed.
Conclusions: In comparison to standard chemotherapeutic strategies, metronomic approaches, though more
patient-friendly, result in a significantly more prominent expansion of regulatory T-cells that aggravate the regulatory to
effector T-cell imbalance. Our findings impact on the modulation of chemotherapy-treated patients’ anti-tumor
immunity and, thus, may be proven useful for selecting the most advantageous drug-delivery strategy, particularly
when immunotherapeutics are eventually to be applied.
Keywords: Metronomic and standard chemotherapy, Regulatory CD4+CD25+ T-cells, Effector CD4+CD25- T-cells,
Regulatory T-cell suppression, Anti-tumour immunityIntroduction
Recently, immune evasion by malignant cells has been
identified as one of the crucial hallmarks of cancer devel-
opment [1]. This evasion may be mediated by immunoe-
diting (i.e. the selection of non-immunogenic tumour-cell
variants) or active immunosuppression of the immune* Correspondence: akoumari@yahoo.com
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article, unless otherwise stated.response [2]. The CD4+CD25+ regulatory T-cells (Tregs)
are the most extensively studied suppressive cells, re-
quired for the regulation of essential immune processes
in allergies, infections, transplantations, autoimmune dis-
eases and neoplasia [3]. Tregs control the activity of ef-
fector T-cells (Teffs) and other immune cells primarily
through cell-to-cell contact, as well as by producing sup-
pressive cytokines (e.g. interleukin-10; IL-10 and trans-
forming growth factor-β; TGF-β) [4].
Increasing evidence suggests that cancer progression
correlates with an increase in Treg activity and a decreaseentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in tumour tissues and/or in the peripheral blood of a
variety of cancer entities and is associated with poor
prognosis and marginal, if any, clinical response to
adoptive immunotherapy [7,8]. Additionally, the ratio of
CD8+ cytotoxic T-cells to Tregs is considered a predictor
of the patients’ survival [7,9].
Currently, many anti-cancer therapeutic approaches
are applied in the clinical setting, including immuno-
therapies, as anti-tumor vaccination, that require a func-
tional immune system to generate objective responses
[10-12]. However, conventional chemotherapy remains
the standard-of-care and predominantly aims to block
tumour-cell proliferation by targeting the spindle micro-
tubules during cell mitosis, or by interfering in the DNA
sequences during DNA replication in the S phase of the
cell cycle. Recent data suggest that chemotherapy halts
tumour progression also by inducing immune-mediated
anti-cancer responses, such as immunogenic cancer-cell
death and increased immune-susceptibility of tumour
cells [13,14]. However, chemotherapy has also been as-
sociated with poor prognosis due to the selection of
chemotherapy-resistant cancer cells, the impairment of
Teffs and the activation of immune-suppressive mecha-
nisms [12,13,15]. Along these lines, the effect of chemo-
therapy on Tregs, in terms of their frequency in the
periphery and/or at the tumour site, is yet not fully de-
fined and previous reports have generated conflicting
results [16]. This may be a consequence of (a) the non-
uniformity of the applied experimental approaches, in-
cluding the methods used for Treg identification and/or
the estimation of their rate; (b) the fact that these stud-
ies were confined to specific chemotherapy regimens;
and (c) the negligence of the underlying functional state
of the host’s immune system, which is vital for the fate
of cancer patients treated with these regimens. More-
over, the functional consequences resulting from alter-
ations in the Treg to Teff equilibrium, especially within
the CD4+ T-cell compartment, have not been reported.
The importance of such studies emerges also in view ofTable 1 Chemotherapy treatment and drug classes
Drug Category Frequen
Standard administration
Epirubicin Anthracycline 2 W
Paclitaxel Taxane 3 W
Carboplatin Alkylating agent 3 W
Metronomic administration
Vinorelbine Vinca alkaloid 5D
Capecitabine Anti-metabolite 14Q2
Temozolomide Alkylating agent OD
2 W: every 2 weeks, 3 W: every 3 weeks, 5D: every 5 days, 14Q21: 14 days every 21
AUC: area under the curve.novel means of chemotherapy administration. Indeed,
as for today, chemotherapy is not only provided follow-
ing standard intravenous cycles, but, alternatively, via a
metronomic pattern in which the drug is chronically
administered at relatively low, minimally toxic doses
with no prolonged drug-free breaks. In an attempt to
determine to which side the peripheral blood CD4+
Treg-Teff equilibrium tilts during anti-cancer therapies,
we investigated the effects of metronomic (oral) vs.
standard (intravenous) chemotherapy administration
on the cell ratio of peripheral CD4+CD25+ Tregs and
CD4+CD25- Teffs, and on the suppressive capacity of
peripheral Tregs over Teffs, in patients with solid
tumours.
Patients and methods
Patients and blood samples
The study was approved by the Attikon University Hos-
pital Ethics Committee and conducted in conformance
with the Declaration of Helsinki Protocols. All samples
were collected following informed consent. The enrol-
ment criteria included newly diagnosed cancer patients
with various tumours (n = 36) receiving either adjuvant
or first-line chemotherapy; of these, 19 patients received
metronomic treatment and 17 were treated with stand-
ard chemotherapy. Exclusion criteria included previous
treatments with chemotherapy, steroids or other immuno-
suppressive agents. For the standard and metronomic
chemotherapy arms, peripheral blood samples were col-
lected from patients after the first cycle of chemotherapy
and prior to administration of the second cycle. The treat-
ment cycles applied for each chemotherapeutic agent
are presented in Table 1. Control samples were obtained
from patients just prior to treatment initiation, as well
as from 13 healthy blood donors. Patient characteristics
and treatment details are presented in Table 2.
Purification of CD4+CD25- and CD4+CD25+ T-cells
Peripheral blood mononuclear cells (PBMCs) were freshly




30 mg Breast, lung, prostate
1 2000 mg Colorectal
100 mg Colorectal
days, OD: once daily (the cycle of chemotherapy treatment was 3 weeks),
Table 2 Characteristics of patients included in the study
Features
Type of cancer
Total Breast Lung Colorectal Ovarian Prostate
(n = 36) (n = 16) (n = 7) (n = 6) (n = 4) (n = 3)
General
Age at diagnosis, median (range) in years 60 (46–86) 52 (46–66) 65 (55–74) 60 (50–86) 67 (59–79) 75 (69–75)
Gender, n (%)
Male 14 (39) 0 6 (86) 4 (66) 0 3 (100)
Female 23 (61) 16 (100) 1 (14) 2 (33) 4 (100) 0
Early/advanced disease, n (%)
Early 17 (47) 10 (63) 2 (29) 2 (33) 3 (75) 0
Advanced 19 (53) 6 (38) 5 (71) 4 (66) 1 (25) 3 (100)
Survival, n (%)
Alive 29 (81) 15 (94) 7 (100) 4 (66) 1 (25) 2 (67)
Deceased 8 (19) 1 (8) 0 2 (33) 3 (75) 1 (33)
Clinical status
PSa, median (range)
At diagnosis/prior to treatment 1 (0–3) 0 (0–2) 1 (0–3) 1 (0–3) 0 (0–1) 2 (1–3)
During treatment 1 (0–3) 0 (0–2) 1 (0–2) 0 (0–3) 0 (0–1) 1 (1–1)
Blood counts
WBCb (×103/μL), median (range) 7.1 (4.0–24.9) 7.1 (5.0–12.8) 8.2 (5.2–24.9) 5.8 (4.5–6.4) 7.8 (6.1–9.5) 7.2 (4.0–8.0)
Lymphocytes (×103/μL), median (range) 1.5 (0.0–3.6) 1.4 (0.0–2.6) 2.1 (1.0–3.1) 1.2 (0.9–1.4) 1.8 (0.5–2.4) 1.5 (1.2–1.9)
% Lymphocytes, mean ± SEc 20.8 ±1.6 20.7 ± 3.6 24.6 ± 1.9 22.1 ± 2.2 23.2 ± 5.0 19.3 ± 3.4
Chemotherapy regime
Administration route, n (%)
Metronomic (oral) 19 (53) 5 (31) 5 (71) 6 (100) - 3 (100)
Standard (intravenous) 17 (47) 11 (69) 2 (29) - 4 (100) -
Drug target, n (%)
Anti-mitotic (alkylating agents, vinca alkaloids) 19 (53) 11 (69) 5 (72) - - 3 (100)




5 (14) - 1 (14) - 4 (100) -
aPS: performance status according the ECOG/WHO scale; bWBCs: white blood cells; cSE: standard error.
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Aldrich, Chemie GmbH, Germany). The CD4+CD25-
Teffs and CD4+CD25+ Tregs were separated by magnetic-
bead sorting using the CD4+CD25+ regulatory T-cell isola-
tion kit (Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions and as previ-
ously described [17,18]. Specifically, the isolation of Teffs
and Tregs was performed in a two-step magnetic labelling
procedure. Briefly, in the first step, isolated PBMCs were
incubated with a cocktail of primary biotin-conjugated
monoclonal antibodies (mAbs) against CD8, CD14, CD15,
CD16, CD19, CD36, CD56, CD123, TCRγ/δ, and CD235a,
and secondary anti-biotin mAbs (isotype mouse IgG)
conjugated to microbeads. CD4+ T-cells were negativelyselected by separation over an appropriate magnetic col-
umn (MACS® Separation LS Columns, Miltenyi Biotec)
placed in a suitable magnetic field (MACS® Separator,
Miltenyi Biotec). In the second step, the CD4+ T-cell fraction
was incubated with CD25-conjugated microbeads. Positive
and negative selection of labeled CD4+CD25+ Tregs and
unlabeled CD4+CD25- Teffs, respectively, was performed
over a second column (MACS® Separation MS Columns).
To further enrich the Treg fraction, CD4+CD25+ cells
were additionally separated over a third column. Cell
purity was assessed by flow cytometry. Cells were stained
with APC-, FITC-, PE-, or PerCP/Cy5.5-conjugated mAbs
to human CD25 (M-A251), CD4 (SK3), FOXP3 (259D/C7)
and CD45RA (HI100), respectively, or CD25-APC and
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according to manufacturer’s instructions. Samples were
analysed using FACSCanto II (Becton-Dickinson (BD)
Biosciences, Erembodegem, Belgium), while data acquisition
and analysis were performed using the FACSDiva software
(BD Biosciences) (Figure 1).
Treg and Teff frequency was expressed as percentage
on gated CD4+ T-cells. The cell number ratio of Tregs
to Teffs was exported from the formula: [%Tregs/CD4+
T-cells] / [%Teffs/CD4+ T-cells].
CD4+CD25- and CD4+CD25+ T-cell cultures
The suppressive capacity of CD4+CD25+ Tregs over
CD4+CD25- Teffs was examined in co-cultures of the
two freshly purified T-cell subpopulations (Teffs + Tregs
co-cultures) in the presence of CD2, CD3 and CD28
antibodies (Tregs Suppression Inspector; Miltenyi Biotec)
following the manufacturer’s instructions and as described
[17-19]. Suppression was initially estimated in selected
samples using serial dilutions ranging from a Teff:Treg ratio
of 1:1 to 8:1 and the ratio of 4:1 was selected for further
screening. Control Teffs and Tregs were separately cultured
with and without stimulus. All cultures were performed in
triplicates (Additional file 1: Figure S1).
Briefly, Tregs and Teffs were suspended in RPMI 1640
(Biochrom AG, Berlin, Germany) supplemented with
10% heat-inactivated normal non-immune foetal bovine
serum, 2 mM L-glutamine, 10 mM Hepes, 5 μg/mL gen-
tamycin, 10 U/mL penicillin and 10 U/mL streptomycin
(all from Gibco Life Technologies, GmbH, Germany) at
5×105 cells/mL. Cells were distributed in round-bottom
96-well microtitre plates and incubated at 5% CO2 in a
humidified chamber maintained at 37°C, for 96 hours.
Proliferation assay
Cell proliferation of individually cultured and co-cultured
CD4+CD25- Teffs and CD4+CD25+ Tregs was evaluated
using a colorimetric enzyme-linked immunosorbent assay
(ELISA) kit (Cell Proliferation ELISA, BrdU-colorimetric,
Roche Applied Science, Mannheim, Germany), according
to the manufacturer’s instructions and as previouslyFigure 1 Treg purity as assessed by flow cytometry. Magnetically purif
CD45RA or CD25 and CD127. Numbers indicate percentages of positive ce
representative cancer patient of 6 tested.described [20]. Incorporation of the 5-bromo-2′-deoxyrinide
(BrdU) pyrimidine analogue in the DNA of replicat-
ing cells, was determined as optical density (OD)
measured at 450 nm with an ELISA reader (EL×800
Absorbance Microplate Reader, BioTek Instruments Inc,
Bad Friedrichshall, Germany). The percentage of Teff
suppression was calculated according to the formula:
1-(OD Teffs + Tregs / OD Teffs) × 100.
Measurement of cytokine levels in culture supernatants
TGF-β and IL-10 levels in culture supernatants were
evaluated with commercial ELISA kits (Quantikine
Immunoassay, R&D System, MN, Minnesota, USA),
according to manufacturer’s instructions. OD was mea-
sured at 450 nm using an ELISA reader (BioTek). All
samples were tested in triplicates. Cytokine levels are
expressed as concentration values in pg/mL.
Statistical analysis
Statistical analysis of the data was performed with
Mann–Whitney or paired-t tests, where appropriate, on
the GraphPad-Prism 5.0 software (GraphPad Software,
San Diego, CA). The tests were two-sided and the sig-
nificance was defined as p-value < 0.05. Only statistically
significant differences are reported.
Results
Metronomic chemotherapy increased the Tregs/Teffs ratio
in the peripheral blood of cancer patients
In accordance with previous reports [7], the Treg/Teff
ratio was elevated in peripheral blood samples of non-
treated cancer patients (mean ratio 0.029) in comparison
to healthy donors (0.020; Figure 2A). After the first cycle
of chemotherapy (metronomic or standard), these patients
exhibited a statistically significant increase in peripheral
Treg/Teff ratios (Figure 2B). It should be noted that this
increase was more pronounced in patients treated with
metronomic chemotherapy (0.209; p = 0.0007), than in
those treated with standard chemotherapy (0.093; p = 0.021;
Figure 2B). The differences recorded between the twoied Tregs were stained with mAbs to human CD25, CD4, FOXP3 and
lls in the purified population. Shown dot plots are from one
Figure 2 Chemotherapy increases the number of Tregs. Differential distribution of Treg/Teff ratio in the peripheral blood of (A) healthy
donors (HD) and non-treated cancer patients (Ca pts), and (B) Ca pts before chemotherapy (Pre-CTx) and patients after the first cycle of metronomic
or standard chemotherapy administration. All samples were analyzed in duplicates. Shown are mean ratios ± SE. *p < 0.05, ** p < 0.01; *** p < 0.001, as
estimated by the Mann–Whitney test.
Figure 3 Metronomic chemotherapy affects the number and
function of Tregs. (A) Teff proliferation was measured by the cell
proliferation assay and expressed as mean optical densities (OD) at
450 nm ± SE. Teffs, single cultures of Teffs; Teffs + Tregs, co-cultures
of Teffs with autologous Tregs at a ratio 4:1. (B) Treg-induced
suppression of Teff proliferation. Shown are mean % values ± SE.
Pre-CTx, patients before chemotherapy administration. All samples
were analyzed in triplicates. * p < 0.05, ** p < 0.01, as estimated by
paired-t test.
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(p = 0.003; Figure 2B).
The suppressive capacity of Tregs was more pronounced
in metronomic than in standard chemotherapy-treated
patients
In accordance with previous data [17-19], the isolated
peripheral blood CD4+CD25- Teffs stimulated with CD2,
CD3 and CD28 antibodies exhibited a marked prolifera-
tive response, while the stimulated CD4+CD25+ Tregs a
hypo-proliferative response (anergy; Additional file 1:
Figure S1). Moreover, the co-culture of stimulated Tregs
and Teffs (Teffs + Tregs co-cultures) resulted in reduced
proliferation of the latter (Figure 3A).
Of note, this reduction was greater after chemotherapy
administration (metronomic or standard). Specifically, in
patients who completed the first chemotherapy cycle,
the proliferation rate of peripheral blood Teffs was sig-
nificantly reduced when these cells were co-cultured
with autologous Tregs (Teffs + Tregs co-cultures), com-
pared to Teffs cultured alone (absolute OD 0.31 vs 0.41,
for the metronomic treatment (p = 0.0016) and 0.15 vs.
0.31, for the standard treatment (p = 0.0099); for Teffs +
Tregs vs. Teffs, respectively; Figure 3A). Although some
reduction in Teff proliferation was also observed in sam-
ples from cancer patients prior to chemotherapy adminis-
tration (0.33 vs. 0.38, for Teffs + Tregs vs.Teffs; Figure 3A),
this was marginal compared to that noted in chemotherapy-
treated patients.
More interestingly, by determining the percentage of
Treg-induced suppression on Teff proliferation, we ob-
served that this was much higher (by ~2.5-fold) in the
peripheral blood of patients undergoing metronomic
chemotherapy (44.42%), compared to suppression in-
duced in patients treated with standard chemotherapy
approaches (16.86%; Figure 3B). The lowest Treg-inducedsuppression was detected in untreated patients (10.65%).
In accordance to this observation was the statistically sig-
nificant difference in % Teff suppression recorded between
the pre-treatment and metronomic treatment groups
(p = 0.044, Figure 3B).
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chemotherapeutic drug administered
To assess whether the differential mode of action of che-
motherapeutics impacts both on Treg number and func-
tionality, we further classified chemotherapy-treated
patients in subgroups based on the drug target: anti-
mitotic (e.g. alkylating agents, vinca alkaloids, taxanes,
anti-microtubules agents) and/or anti-DNA (e.g. alkylat-
ing agents, anti-metabolies, anthracyclines). Our results
revealed that among the regimens applied in a metro-
nomic pattern, administration of anti-mitotic and anti-
mitotic/anti-DNA schemes was associated with higher
Treg/Teff ratios (0.243 and 0.245, respectively), com-
pared to anti-DNA drugs (0.146; Figure 4A). Moreover,
the activity of Tregs from these 2 groups was increased,
and co-culture of the two subpopulations, induced a sig-
nificant suppression of autologous Teff proliferation (for
the anti-mitotic drugs, 0.09 vs. 0.16 for Teffs + Tregs vs.
Teffs, respectively; p = 0.018; for the anti-mitotic/anti-
DNA combination, 0.36 vs. 0.13 for Teffs + Tregs vs.
Teffs, respectively; Figure 4B). To reveal a potential
mechanism of the recorded Teff suppression, we used
cytokine-specific ELISAs to determine the levels ofFigure 4 Effect of the type and means of chemotherapy
administration on Tregs. (A) Differential distribution of Treg/Teff
ratio in the peripheral blood of patients treated with anti-mitotic,
anti-DNA or combined (anti-mitotic/anti-DNA) regimens in a
metronomic or standard pattern. Shown are means ± SE. All samples
were analyzed in duplicates. (B) Teff proliferation expressed as mean
OD at 450 nm± SE. All samples were analyzed in triplicates. Other
details as in Figure 2. * p<0.05, ** p<0.01, as estimated by Mann–Whitney
or paired-t test.TGF-β and IL-10 in culture supernatants. Among the
metronomically administrated drugs, the anti-mitotic
group was associated with the highest levels of IL-10
(>2-fold) and TGF-β (>1.5-fold), compared to the anti-
DNA group or the anti-mitotic/anti-DNA combination.
These data suggest that the high numbers of Tregs de-
tected in the peripheral blood of patients treated with
metronomic chemotherapy, were active and secreted
suppressive cytokines.
Within the group of patients receiving standard chemo-
therapy, the anti-DNA-treated subgroup showed the high-
est ratio of Tregs/Teffs (0.316 compared to 0.080 and
0.084 of the anti-mitotic- and anti-mitotic/anti-DNA-ad-
ministered subgroups, respectively; Figure 4A). However,
significant repression of Teff proliferation by Tregs was
detected only in the anti-mitotic subgroup (0.09 vs.
0.16, for Teffs + Tregs vs. Teffs, respectively; p = 0.018;
Figure 4B). This correlated with higher levels of sup-
pressive cytokines characterizing the anti-mitotic sub-
group (>2.5-fold for IL-10, and >2-fold for TGF-β),
compared to the values determined in samples belong-
ing to the anti-DNA or anti-mitotic/anti-DNA chemo-
therapy subgroups.
Further analysis of our results showed that metronomic
administration of anti-mitotic agents, either alone or in
combination with anti-DNA drugs, resulted in a higher
Treg/Teff ratio, compared to standard administration
(0.243 vs. 0.080, p = 0.0064 for the anti-mitotic agents;
0.245 vs. 0.084, p = 0.034, for the combination of anti-
mitotic/anti-DNA regimens; Figure 4A).
The above referred observations suggest that anti-
mitotic regimens, particularly if given metronomically,
act in favour of Tregs more potently than anti-DNA
agents or the combination of the two.
Breast cancer patients treated with metronomic
chemotherapy have increased numbers of functionally
competent Tregs in their peripheral blood
To further associate the effect of metronomic vs standard
chemotherapy in a specific type of cancer, we selected
breast cancer patients from our cohort and analysed both
the number and the activity of peripheral blood Tregs. As
shown in Figure 5, the favourable effect of chemotherapy
on Treg/Teff ratio was more prominent in patients receiv-
ing metronomic than standard chemotherapy (0.179 and
0.098, respectively) and these values were much higher in
both treatments compared to the Treg/Teff ratio in pre-
chemotherapy breast cancer patients (0.009) (p = 0.0096
or p = 0.031 for pre-chemotherapy vs. metronomic or
standard groups, respectively, Figure 5A). Accordingly, a
statistically significant decrease in Teff proliferation upon
co-culture with autologous Tregs was associated with the
administration of either metronomic (0.13 vs. 0.69 for Teffs
vs. Teffs +Tregs, respectively; p= 0.04) or standard treatment
Figure 5 Effect of metronomic and standard chemotherapy on breast cancer patients. (A) Differential distribution of Treg/Teff ratio in the
peripheral blood of breast cancer patients prior chemotherapy administration (Pre-CTx) and after metronomic or standard treatment. Shown are
mean values ± SE. All samples were analyzed in duplicates. (B) Teff proliferation expressed as mean OD at 450 nm± SE. (C) Treg-induced suppression
on Teff proliferation. Shown are mean % values ± SE. All samples were analyzed in triplicates. Other details as in Figure 2. * p < 0.05 and ** p < 0.01 as
estimated by Mann–Whitney or paired-t tests.
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p = 0.05) (Figure 5B). However, higher percentages of
Tregs-induced suppression of Teffs (41.10%) were noticed
in the group of patients treated with metronomic
chemotherapy compared to that estimated after standard
administration of the agents (27.59%), as well as in
pre-chemotherapy breast cancer patients (20.77%; Figure 5C).
These results, although preliminary and acquired using a
limited number of samples, show that even one cycle of
metronomic chemotherapy administration increases the
suppressive functions of Tregs, and suggest that prolonged
treatment may possibly abrogate the integrity of immune
responses.
Discussion
For over a decade, metronomic chemotherapy has been
proposed as an alternative to conventional drug adminis-
tration in cancer patients. Metronomic administration
comprises 3 characteristics: (1) it is frequent, often on a
daily basis; (2) it is continuous, with no drug-free breaks
and (3) the doses are lower than the maximum tolerated
dose [21,22]. Its low toxicity and cost, ease of adminis-
tration and efficacy justify the continuously increasing
number of reports, both in animals and in humans, in
support of its use. Metronomic chemotherapy, although
initially shown to inhibit angiogenesis and reduce the
levels of some biological markers (e.g. VEGF) is now
proven to modulate immune responses, by increasing
the de novo generation of tumor-specific effector T-cells,
re-sensitize pre-existing suppressed tumor-reactive T-,
NK- and NKT-mediated responses and induce the mat-
uration of dendritic cells [21,23]. Numerous studies ad-
dressed the effect of metronomic chemotherapy on
specific types of cancer, using a specific drug and a spe-
cific regime [22,24]. However, only few reports refer to
the direct comparison of immune parameters in metro-
nomic vs. standard chemotherapy in cancer patients[22,25]. This prompted us to study the possible derange-
ment, both in cell numbers and functionality, of the per-
ipheral effector/regulatory T-cell equilibrium in patients
with various solid tumors, using chemotherapeutics with
different, albeit precise, modes of action, focusing in
principle on the comparative investigation between metro-
nomic and standard chemotherapy strategies. In contrast
with earlier reports, where either the Tregs or Teffs were
examined, this study explores the chemotherapy impact
on the balance between the two, regulatory and effector,
T-cell subpopulations. Moreover, the functional and nu-
merical parameters of Tregs/Teffs are investigated in asso-
ciation with the manner of chemotherapy administration
(metronomic or standard) and the mode of action of
the chemotherapeutic agent (anti-mitotic or anti-DNA
or both).
Due to several inconsistencies as for the identification of
peripheral blood Tregs and in order to ensure that the
populations studied herein are those of interest, we ini-
tially evaluated our T-cell (Tregs and Teffs) purification
protocol in healthy donors and cancer patients prior and
during chemotherapy. In agreement with data available in
the literature [26-29], healthy donors had low numbers of
Tregs, which increased in cancer patients and were further
augmented upon chemotherapy administration. Moreover,
irrespective of the means of administration (metronomic
or standard), chemotherapy reduced the relative numbers
of CD4+CD25- Teffs and augmented the suppressive ef-
fect of Tregs on Teffs. Our results are in line with previous
reports where patients with haematologic malignancies
demonstrated a marked Teff suppression, indicating
that lymphocyte recovery after chemotherapy may aug-
ment Treg proliferation [20]. Lymphopenia characterizing
cancer patients offers a possible explanation to the ob-
served Treg enforcement, as described by Haribhai et al.
(2009) [30]. In a lymphopenic environment, members
of the naïve T-cell repertoire, irrespective of their
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compartment and finally contribute to the deregulation of
Teff expansion [30].
In our cohort of patients, metronomic administration
exerted a more intense immunosuppressive effect com-
pared to standard treatment, acting in favour of Tregs
and against Teffs. As shown, metronomic chemotherapy
increased the number of Tregs and the secretion of
TGF-β and IL-10, and reduced Teff proliferation. The
increase in the number of Tregs we observed, is in con-
trast to most studies published to date which suggest
that metronomic approaches deplete Tregs and improve
cancer patients’ immunocompetence [22,25]. However,
our data are in agreement with the most recent elegant
study of Ge et al. [31] revealing that metronomic cyclo-
phosphamide treatment only transiently reduced the
number of Tregs in breast cancer patients and Treg pro-
liferation fully recovered after 4–6 weeks of ongoing
treatment, and with Ellebaek et al. [32] who showed a
pronounced Treg increase in melanoma patients treated
with metronomic cyclophosphamide administered in con-
junction with a Cox-2-inhibitor and a DC-based multi-
epitope vaccine. The reasons for the contradictory effects
of metronomic chemotherapy on Tregs are not clear.
They could be explained by the significantly higher regen-
eration rate of Tregs (approximately 8 days) compared to
Teffs (24 days for memory; 199 days for naive) [33], allow-
ing Tregs to return to their normal cell cycling and growth
in the thymus or in peripheral lymph nodes, and their
prompt re-enter in circulation. Teffs cannot be as rapidly
recruited, since following their activation, antigen-
stimulated T-cells have been reportedly shown to enter a
transient refractory state that lasts for several additional
days [17]. We speculate that the doses and the schedule of
drug administration, the type and stage of cancer, the
mode of action of the chemotherapeutic drug, the basal
status of the immune system of each patient at treatment
initiation, or combinations thereof may additionally ac-
count for the inconsistencies reported. For example, the
Treg/Teff balance may be relevant to the divergent bio-
availability of orally (metronomic) and intravenously
(standard) administered drugs, associated with different
opportunities for the Treg and Teff populations to re-
cover. Moreover, in regard to the specific drugs mode of
action, and although our analysis was performed on a
small number of samples, our data indicate that chemo-
therapeutics targeting the microtubules of the spindle dur-
ing mitosis (anti-mitotic drugs) are associated with higher
Treg numbers and an increased Treg-induced suppression
of Teffs, in comparison with those regimens that interfere
with the DNA sequence during the S phase of the cell-
cycle (anti-DNA drugs), or a combination of the two.
Although ongoing in vitro experiments will explicate
our initial observation, these variations in the drugs’targets could be associated with the aforementioned dif-
ferences in cell cycling between Tregs and Teffs.
The functional analysis of Tregs expanded in vivo upon
metronomic chemotherapy verified their ability to sup-
press specific immune activities. When Tregs purified
from the peripheral blood of patients treated with one
cycle of metronomic chemotherapy were cultured ex vivo,
they secreted high levels of IL-10 and TGF-β and sig-
nificantly suppressed autologous Teff proliferation. Teff
suppression was more prominent in patients receiving
anti-mitotic drugs and was positively correlated both
with the recorded high Treg/Teff ratios and the deter-
mined increased levels of IL-10 and TGF-β.
No matter the reason(s), the finding that metronomic
administration enhances the number and function of
Tregs, as shown by us (this report) and others [31,32], is
essential and should be considered when selecting the
appropriate chemotherapy strategy, particularly in cases
where the use of chemotherapy prior to vaccination may
hinder the efficacy of the vaccine. Since combined vac-
cination and chemotherapy strategies often fail to show
survival benefit, this could merely be an underlying
cause [16].
Due to its advantages, the application of chemotherapy
in a metronomic manner is a desirable objective, espe-
cially in types like breast cancer, where the patient can
be treated at home, experience less toxic side effects and
avoid hospitalization [21,22]. However, the selective ana-
lysis of our breast-cancer group indicated that metro-
nomic chemotherapy enforced the Treg population to a
greater extent than standard administration. Hence, con-
firming our results from the entire cohort, these data
suggest that metronomic compared to standard chemo-
therapy, results in a more unfavourable, as for the pa-
tients’ outcome, Treg-Teff interaction.
We cannot exclude the possibility that the shift in
Treg/Teff ratio observed in this study may reflect more
complex underlying mechanisms among the host, the
tumour and the regimen. Although the Treg-Teff tug-of-
war is important, other immune components that may
also be affected by chemotherapy play a crucial role in
the host’s homeostasis, including myeloid-derived sup-
pressors [5,6], macrophages and/or NK cells [34-39].
Thus, the contribution of the reported chemotherapy-
enhanced Treg suppressive activity against Teffs to tumour
immune-escape, needs to be further explored.
More studies are warranted to clarify the impact of the
interplay between chemotherapeutic agents and immune
cells in the effectiveness of the anti-tumor immunity
and, therefore, in the success of the treatment strategy.
The extensive exploration of each tumour’s features in
association with the immunological profile of the patient
is vital for the development of personalised therapeutic
interventions, where the manner of administration and
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Conclusion
The current study supports that in comparison with
standard anti-cancer treatment strategies, the alterna-
tive approach of metronomic chemotherapy, though
more patient-friendly, prominently acts in favour of
Tregs, and impairs the regulatory-to-effector T-cell im-
balance against the host’s anti-tumor immunity. The
findings on this immune-related impact of chemother-
apy may be proven useful in the clinicians’ selection of
the most advantageous drug-delivery strategy, particu-
larly in cases when immunotherapeutics are eventually
to be applied.
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